Identify the Signs and Symptoms of Scarring Alopecia modernsalon.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from modernsalon.com Daily Mail and Mail on Sunday newspapers.
The investigational drug deuruxolitinib is effective for hair regrowth in patients with alopecia areata, putting it in line to become second approved JAK inhibitor.
Eli Lilly Says 2nd Late-stage Study Of Baricitinib Achieved Main Goal
AA is an autoimmune disease that causes patchy hair loss.
The data from the second Phase 3 study of baricitinib in AA, dubbed BRAVE-AA1, are consistent with the first Phase 3 study, dubbed BRAVE-AA2, top-lined earlier this year.
In both studies, a statistically significant proportion of patients treated with baricitinib 2-mg and 4-mg achieved the primary endpoint of hair regrowth at Week 36 compared to patients treated with placebo, the companies said. There is a pressing need for approved treatment options for people suffering from alopecia areata as existing topicals and steroids do not provide meaningful improvement for many patients, said Maryanne Senna, dermatologist and assistant professor of dermatology at Harvard Medical School and clinical trial investigator of BRAVE-AA1.